ContraFect (ContraFect) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is ContraFect 3-Year Dividend Growth Rate?

ContraFect's Dividends per Share for the three months ended in Sep. 2023 was $0.00.

The historical rank and industry rank for ContraFect's 3-Year Dividend Growth Rate or its related term are showing as below:

CFRXQ's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.5
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

ContraFect's Dividend Payout Ratio for the three months ended in Sep. 2023 was 0.00. As of today, ContraFect's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of ContraFect's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, ContraFect's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ContraFect's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where ContraFect's 3-Year Dividend Growth Rate falls into.

ContraFect 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

ContraFect (OTCPK:CFRXQ) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

ContraFect's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.613
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ContraFect 3-Year Dividend Growth Rate Related Terms>

ContraFect (ContraFect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701

Website

https://www.contrafect.com

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

Executives

Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger	officer: VP Finance	238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff	director	1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low	director	EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi	director	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner	officer: SVP Business Development	30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	10 percent owner	BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd	10 percent owner	FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino	officer: Chief Medical Officer	757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos	officer: General Counsel	207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto	director	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421